TGF  Blockade as Anticancer Therapy

Teicher, Beverly A.; Yingling, Jonathan M.; McPherson, John M.

doi:10.1158/aacr.edb-08-8179

Cited by 1 publication

(1 citation statement)

References 37 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although several clinical trials of TGF-β1 antagonists for cancer treatment are underway, 32 the main concern is that TGF-β1 antagonists could enhance the proliferation of tumor cells, which may counterbalance their potential therapeutic benefits on immunomodulation. 33 A recent study has shown that the processing of pri-microRNA could be selectively blocked. 34 miR-1245 could, therefore, be a promising target for tumor immunotherapy to improve NK cell activity.…”

Section: T a S T O R T I F O U N D A T I O Nmentioning

confidence: 99%

Human microRNA-1245 down-regulates the NKG2D receptor in natural killer cells and impairs NKG2D-mediated functions

et al. 2012

View full text Add to dashboard Cite

We investigated the potential interactions between the 3'-untranslated region of the NKG2D gene and microRNA as well as their functional roles in the regulation of NKG2D expression and cytotoxicity in natural killer cells. ResultsTransforming growth factor-β1, a major negative regulator of NKG2D expression, post-transcriptionally up-regulated mature microRNA-1245 expression, thus down-regulating NKG2D expression and impairing NKG2D-mediated immune responses in natural killer cells. Conversely, microRNA-1245 down-regulation significantly increased the expression of NKG2D expression in natural killer cells, resulting in more efficient NKG2D-mediated cytotoxicity. ConclusionsThese results reveal a novel NKG2D regulatory pathway mediated by microRNA-1245, which may represent one of the mechanisms used by transforming growth factor-β1 to attenuate NKG2D expression in natural killer cells. © F e r r a t a S t o r t i F o u n d a t i o n © F e r r a t a S t o r t i F o u n d a t i o n

show abstract

Section: T a S T O R T I F O U N D A T I O Nmentioning

confidence: 99%